Multiple myeloma prognosis: what to know

A haematology team considers laboratory findings, the genetic features of the myeloma cells, kidney function, blood counts, bone involvement, symptoms, and general fitness. The response seen on follow-up tests also matters. Myeloma may become quieter after treatment and later become active again, so prognosis is updated as new information appears rather than fixed from one test.

Keep appointments for blood and urine monitoring and tell the team about new pain, infections, numbness, fatigue, or changes in urination. Ask for the purpose of each test and what result would change the plan. Treatment may involve chemotherapy, targeted therapy, a stem-cell transplant, cellular therapy, radiotherapy for a focused problem, and bone-strengthening treatment. Supportive care can protect function and help you stay involved in decisions.

Contact your care team urgently for fever, new breathlessness, chest pain, marked confusion, severe weakness, sudden loss of bladder or bowel control, or new leg weakness. Severe back pain or inability to move a limb also needs prompt assessment because myeloma can affect bones and the spine.

Ask which disease features affect your outlook, how treatment response will be measured, what signs suggest the illness is active, and which options would be considered if it returns. Ask how kidney, bone, nerve, and infection risks will be followed.